Mounjaro®
Starting from £179.99/mo
Start journey Learn moreNot feeling the Mounjaro injection is completely normal, and it is one of the most common things people mention after their first pen. The KwikPen's needle is very fine and short, and most people feel little or nothing at all during the injection itself. What matters is not the sensation in the moment but the steady, slow absorption of tirzepatide into the tissue beneath the skin, a process that takes place over days rather than seconds. These are prescription-only medicines requiring clinical assessment before you start, and your prescriber is always the right person to contact if you have specific concerns about your individual experience.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The Mounjaro KwikPen is designed for self-injection using a needle that is narrow enough to pass through the skin with minimal stimulation of nerve endings. Many people press the pen against their abdomen, click the plunger, hold it in place for ten seconds, and then look at the pen wondering whether something went wrong, because they felt almost nothing. That is the intended experience, not a malfunction.
What varies between people is the texture of the moment: some describe a brief, cold pressure; others a mild pinch that fades immediately; others truly nothing at all. A small number notice a slight stinging sensation, usually if the injection site is cold or if the pen has only just come out of the fridge. The injection site you choose plays a part too, the abdomen tends to be the most comfortable for most people, while the thigh can be marginally more sensitive depending on muscle distribution.
None of these variations tells you whether the dose went in correctly. The KwikPen's mechanism pushes the full dose of tirzepatide into the subcutaneous layer when the plunger is depressed; the sensation on the surface of the skin is largely irrelevant to that process. If the dose window on the pen shows it has been delivered, it has been delivered. You can read more about how the pen itself is designed and what to check in our guide to the Mounjaro injection pens.
Once tirzepatide enters the subcutaneous tissue, absorption is gradual. Peak plasma levels are typically reached around 24 to 48 hours after injection, which is why you do not walk away from a Wednesday-morning injection feeling different by Wednesday afternoon. The drug is then active across the full seven-day dosing window before your next injection is due.
This slow-release profile is what makes once-weekly dosing possible, and it is also what catches people out. If you inject on a Monday morning and then spend Monday waiting to feel something, you are watching the wrong clock entirely. The clinical effects (reduced hunger, food feeling satisfying in smaller quantities, less interest in snacking) tend to build quietly over the first seven to fourteen days, often in a way that is easier to spot in retrospect than in the moment. You might find yourself halfway through a meal and simply not wanting the rest, without ever feeling a sharp shift in appetite.
The NHS information on tirzepatide notes that how long effects take to become noticeable varies between individuals, particularly at the 2.5mg starting dose, which is calibrated for tolerability rather than maximum effect. If you are curious about when to expect the effects to come through, that question has its own detailed answer. The NICE appraisal of tirzepatide (TA1026) drew on trials where meaningful weight reduction accumulated over many weeks (not days) which reflects exactly this gradual mechanism.
There is a difference between feeling nothing at the moment of injection, which is expected, and having a specific reason to think the dose may not have entered the tissue at all. The latter is rare but worth knowing about. After you hold the pen in place for the recommended ten seconds and withdraw it, check the following: the plunger should have moved to its endpoint and the dose indicator should confirm delivery. A very small droplet of clear fluid occasionally appears at the injection site as the needle is withdrawn, this is normal and does not represent a significant lost portion of the dose.
What would give more legitimate grounds for concern: the pen tip was not properly attached, you held the pen at a sharp angle rather than straight against the skin, or the pen was not pressed firmly enough to activate. If any of those apply, do not inject a second time. Contact your prescriber or our aftercare team (who are available seven days a week) before taking any further action. Doubling a dose of tirzepatide is not the right response to uncertainty, and your prescriber will guide you on what to do. The NHS tirzepatide page also covers missed and uncertain doses in its patient guidance.
Keeping the injection area clean before use is straightforward; an alcohol swab wiped over the skin and allowed to dry takes seconds and is a good habit. Rotating your site between the abdomen, thigh, and upper arm each week helps with absorption consistency and prevents localised skin changes. A detailed look at choosing and rotating your injection site is worth reading if you are new to the process.
This is a different question and worth separating clearly. If several weeks pass on a given dose and you have noticed no change in appetite or weight, that is worth raising with your prescriber, not because something necessarily went wrong, but because dose titration exists precisely for this reason. Tirzepatide is titrated through 2.5mg, 5mg, 7.5mg and higher strengths in stages, and some people's response genuinely improves as the dose increases. Your prescriber at each review will look at your progress and decide whether continuing at the current dose or moving upward is the right clinical call.
It is also worth pausing to consider the broader picture. Tirzepatide works alongside a reduced-calorie diet and increased activity, not instead of them. If eating habits have not shifted much alongside treatment, the appetite-reduction signal can be harder to detect. Many people find it helpful to read about what to expect after the first injection before drawing conclusions about whether the medicine is working.
If you are not yet on Mounjaro but are considering it, the full Mounjaro overview covers the clinical evidence, who it is licensed for, and how to access it through a regulated private pharmacy. For context on what private treatment involves and how pricing works, the weight-loss treatments overview sets that out plainly. These are prescription-only medicines, so the process always starts with a clinical consultation, our prescribers review every application the same day it is submitted, and the consultation itself is free. You can start your free consultation whenever you are ready.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.